Antibody-Mediated Rejection With a Striking Interstitial Monocyte/Macrophage Infiltration in a Renal Allograft Under FTY720 Treatment

American Journal of Kidney Diseases

Volumn 51, Issue 1, 2008, Pages 127-130

  Sis, Banu ^a   Grynoch, Richard ^a   Murray, Allan G ^a   Campbell, Patricia ^a   Solez, Kim ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

acute allograft rejection; antibody mediated rejection; C4d; FTY720; kidney; lymphocyte depletion; pathology; transplantation

Indexed keywords

ANTIBODY; CD68 ANTIGEN; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOSPORIN A; FINGOLIMOD; GLOBULIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; B LYMPHOCYTE; CAPILLARY; CASE REPORT; CELL INFILTRATION; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; GRAFT RECIPIENT; HEALTH CARE ORGANIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TUBULE; LOW DRUG DOSE; MACROPHAGE; MALE; MONOCYTE; MORPHOLOGY; STAINING; T LYMPHOCYTE; THERAPY EFFECT;

ANTIBODIES; CELL MOVEMENT; EXTRACELLULAR FLUID; GRAFT REJECTION; HLA-B27 ANTIGEN; HLA-DR ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PROPYLENE GLYCOLS; SPHINGOSINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 37349073160     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.08.023     Document Type: Article

References (23)

1. Brinkmann V., Cyster J.G., and Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4 (2004) 1019-1025
2. Dragun D., Fritsche L., Boehler T., Peters H., Budde K., and Neumayer H.H. FTY720: Early clinical experience. Transplant Proc 36 suppl 2S (2004) S544-S548
3. Kahan B.D. FTY720: From bench to bedside. Transplant Proc 36 suppl 2S (2004) S531-S543
4. Brinkmann V., Pinschewer D., Chiba K., and Feng L. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 21 (2000) 49-52
5. Chiba K., Yanagawa Y., Masubuchi Y., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160 (1998) 5037-5044
6. Ferguson R. FTY720 immunomodulation: Optimism for improved transplant regimens. Transplant Proc 36 suppl 2S (2004) S549-S553
7. Suzuki S., Enosawa S., Kakefuda T., et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 61 (1996) 200-205
8. Xu M., Pirenne J., Antoniou E.A., Afford S.C., D'Silva M., and McMaster P. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl Int 11 (1998) 288-294
9. Budde K., Schmouder R.L., Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13 (2002) 1073-1083
10. Budde K., Schmouder R.L., Nashan B., et al. Pharmacodynamics of single dose of the novel immunosuppressant FTY720 in stable renal patients. Am J Transplant 3 (2003) 846-854
11. Kahan B.D., Karlix J.L., Ferguson R.M., et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo controlled, phase I study. Transplantation 76 (2003) 1079-1084
12. Tedesco-Silva H., Kahan B., Mourad G., et al. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection (AR) in renal allograft recipients (interim data). Am J Transplant 1 suppl 1 (2001) S243A abstr
13. Tedesco-Silva H., Mourad G., Kahan B., et al. FTY720, a novel immunomodulator-Efficacy and safety results from the first phase 2a study in de novo renal transplantation. Transplantation 79 (2005) 1553-1560
14. Walker R., Ferguson R.M., Mulgaonker S., et al. FTY720 with reduced cyclosporine exposure is efficacious in preventing rejection in renal transplantation: 12-Month preliminary results. Nephrol Dial Transplant 18 suppl 4 (2003) S499A abstr
15. Salvadori M., Budde K., Charpentier B., et al., FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6 (2006) 2912-2921
16. Tedesco-Silva H., Pescovitz M.D., Cibrik D., et al., FTY720 Study Group. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82 (2006) 1689-1697
17. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria-An addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 3 (2003) 1-7
18. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713-723
19. Jose M.D., Ikezumi Y., Van Rooijen N., Atkins R.C., and Chadban S.J. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 76 (2003) 1015-1022
20. Kirk A.D., Hale D.A., Mannon R.B., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76 (2003) 120-129
21. Shimizu H., Takahashi M., Kaneko T., et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111 (2005) 222-229
22. Garside P., Ingulli E., Merica R.R., Johnson J.G., Noelle R.J., and Jenkins M.K. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281 (1998) 96-99
23. Mitchison N.A. T-Cell-B-cell cooperation. Nat Rev Immunol 4 (2004) 308-312